SF4978

Formulary Committee members with a potential conflict of interest permission to participate in committee communications and discussions
Legislative Session 94 (2025-2026)

Related bill: HF4852

Bill text

Introduction

ReadChanges
PDF
(underlined = new law, struck through = current law the bill removes)
1.1A bill for an act
1.2relating to health; permitting Formulary Committee members with a potential
1.3conflict of interest to participate in committee communications and discussions;
1.4requiring the commissioner of human services to develop a public comment process
1.5for recommendations to the Formulary Committee; requiring the Formulary
1.6Committee to seek expertise from the Minnesota Rare Disease Advisory Council;
1.7amending Minnesota Statutes 2024, section 256B.0625, subdivisions 13f, 13g;
1.8Minnesota Statutes 2025 Supplement, section 256B.0625, subdivision 13c.
1.9BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
1.10Section 1. Minnesota Statutes 2025 Supplement, section 256B.0625, subdivision 13c, is
1.11amended to read:
1.12Subd. 13c. Formulary Committee. new text begin (a) new text end The commissioner, after receiving
1.13recommendations from professional medical associations and professional pharmacy
1.14associations, and consumer groups shall designate a Formulary Committee to carry out
1.15duties as described in subdivisions 13 to 13g.
1.16 new text begin (b) new text end The Formulary Committee shall be comprised of at least five licensed physicians
1.17actively engaged in the practice of medicine in Minnesota, one of whom is an actively
1.18practicing psychiatrist, one of whom specializes in the diagnosis and treatment of rare
1.19diseases, one of whom specializes in pediatrics, and one of whom actively treats persons
1.20with disabilities; at least three licensed pharmacists actively engaged in the practice of
1.21pharmacy in Minnesota, one of whom practices outside the metropolitan counties listed in
1.22section 473.121, subdivision 4, one of whom practices in the metropolitan counties listed
1.23in section 473.121, subdivision 4, and one of whom is a practicing hospital pharmacist; at
1.24least two consumer representatives, all of whom must have a personal or professional
1.25connection to medical assistance; and one representative designated by the Minnesota Rare
2.1Disease Advisory Council established under section 256.4835; the remainder to be made
2.2up of health care professionals who are licensed in their field and have recognized knowledge
2.3in the clinically appropriate prescribing, dispensing, and monitoring of covered outpatient
2.4drugs.
2.5 new text begin (c) new text end Members of the Formulary Committee shall not be employed by the Department of
2.6Human Services or have a personal interest in a pharmaceutical company, pharmacy benefits
2.7manager, health plan company, or their affiliate organizations, but the committee shall be
2.8staffed by an employee of the department who shall serve as an ex officio, nonvoting member
2.9of the committee.
2.10 new text begin (d) new text end For the purposes of this subdivision, "personal interest" means that a person owns
2.11at least five percent of the voting interest or equity interest in the entity, the equity interest
2.12owned by a person represents at least five percent of that person's net worth, or more than
2.13five percent of a person's gross income for the preceding year was derived from the entity.
2.14 new text begin (e) new text end A committee member must notify the committee of any potential conflict of interest
2.15and recuse themselves from any deleted text begin communications, discussion, or deleted text end vote on any matter where
2.16a conflict of interest exists. A conflict of interest alone, without a personal interest, does
2.17not preclude an applicant from serving as a member of the Formulary Committee. new text begin The new text end
2.18 new text begin commissioner must publicly disclose any conflict of interest form submitted by a committee new text end
2.19 new text begin member on the Department of Human Services' website at least 48 hours before any meeting new text end
2.20 new text begin of the Formulary Committee that includes the drug subject to the conflict of interest on the new text end
2.21 new text begin agenda. new text end
2.22 new text begin (f) new text end Members may be removed from the committee for cause after a recommendation for
2.23removal by a majority of the committee membership. For the purposes of this subdivision,
2.24"cause" does not include offering a differing or dissenting clinical opinion on a drug or drug
2.25class.
2.26 new text begin (g) new text end The department's medical director shall also serve as an ex officio, nonvoting member
2.27for the committee.
2.28 new text begin (h) new text end Committee members shall serve three-year terms and may be reappointed twice by
2.29the commissioner.
2.30 new text begin (i) new text end The committee members shall vote on a chair and vice chair from among their
2.31membership. The chair shall preside over all committee meetings, and the vice chair shall
2.32preside over the meetings if the chair is not present.
3.1 new text begin (j) new text end The Formulary Committee shall meet at least three times per year. The commissioner
3.2may require more frequent Formulary Committee meetings as needed.
3.3 new text begin (k) new text end An honorarium of $100 per meeting and reimbursement for mileage shall be paid to
3.4each committee member in attendance.
3.5 new text begin (l) new text end The Formulary Committee expires June 30, deleted text begin 2029 deleted text end new text begin 2030 new text end .
3.6 new text begin (m) new text end The Formulary Committee is subject to the Open Meeting Law under chapter 13D.
3.7 new text begin Notwithstanding the foregoing, this paragraph does not prevent: new text end
3.8 new text begin (1) Formulary Committee staff communication with the representative designated by new text end
3.9 new text begin the Minnesota Rare Disease Advisory Council or communication between Formulary new text end
3.10 new text begin Committee staff and Minnesota Rare Disease Advisory Council staff as long as a quorum new text end
3.11 new text begin of the Formulary Committee members are not included in the communication; or new text end
3.12 new text begin (2) Formulary Committee members from seeking clinical expertise in advance of a new text end
3.13 new text begin Formulary Committee meeting. Any such experts may submit, and may be encouraged by new text end
3.14 new text begin Formulary Committee members to submit, public comments. new text end
3.15 new text begin (n) new text end For purposes of establishing a quorum to transact business, vacant committee member
3.16positions do not count in the calculation as long as at least 60 percent of the committee
3.17member positions are filled.
3.18 new text begin (o) In accordance with section 256.4835, subdivision 4, paragraph (a), clause (2), the new text end
3.19 new text begin Formulary Committee must, through the representative of the committee designated by the new text end
3.20 new text begin Minnesota Rare Disease Advisory Council, seek subject matter expertise and input from new text end
3.21 new text begin the Minnesota Rare Disease Advisory Council before taking action under the Formulary new text end
3.22 new text begin Committee's authority relating to prior authorization requirements under subdivision 13f new text end
3.23 new text begin or relating to placement of an orphan drug, as defined in section 152.01, subdivision 21, on new text end
3.24 new text begin the preferred drug list under subdivision 13g. The commissioner is prohibited from entering new text end
3.25 new text begin into or renewing a contract with a pharmacy benefit manager, as defined in section 62W.02, new text end
3.26 new text begin subdivision 15, that would limit the Formulary Committee's obligation and ability to seek new text end
3.27 new text begin the expertise and input described in this paragraph. new text end
3.28 new text begin (p) Within 30 days of Federal Drug Administration approval or modification of an orphan new text end
3.29 new text begin drug, Formulary Committee staff must contact the representative designated by the Minnesota new text end
3.30 new text begin Rare Disease Advisory Council in writing to initiate the process of seeking subject matter new text end
3.31 new text begin expertise from the council. Formulary Committee staff must seek Rare Disease Advisory new text end
3.32 new text begin Council expertise before receiving a recommendation from the vendor contracted with the new text end
3.33 new text begin Department of Human Services for the purpose of participating in a preferred drug list and new text end
4.1 new text begin supplemental rebate program. Once a recommendation is received from the vendor, new text end
4.2 new text begin Formulary Committee staff must share with the Rare Disease Advisory Council any work new text end
4.3 new text begin and documents created for the state that include a proposed action or proposed prior new text end
4.4 new text begin authorization requirement. Once public notice is issued of a Formulary Committee meeting, new text end
4.5 new text begin the Rare Disease Advisory Council may conduct public outreach activities related to any new text end
4.6 new text begin proposed action or proposed prior authorization requirement as long as no communications new text end
4.7 new text begin or activities include a quorum of the Formulary Committee, in compliance with the Open new text end
4.8 new text begin Meeting Law. new text end
4.9Sec. 2. Minnesota Statutes 2024, section 256B.0625, subdivision 13f, is amended to read:
4.10Subd. 13f. Prior authorization. (a) The Formulary Committee shall review and
4.11recommend drugs which require prior authorization. The Formulary Committee shall
4.12establish general criteria to be used for the prior authorization of brand-name drugs for
4.13which generically equivalent drugs are available, but the committee is not required to review
4.14each brand-name drug for which a generically equivalent drug is available.
4.15(b) Prior authorization may be required by the commissioner before certain formulary
4.16drugs are eligible for payment. The Formulary Committee may recommend drugs for prior
4.17authorization directly to the commissioner. The commissioner may also request that the
4.18Formulary Committee review a drug for prior authorization. Before the commissioner may
4.19require prior authorization for a drug:
4.20(1) the commissioner must provide information to the Formulary Committee on the
4.21impact that placing the drug on prior authorization may have on the quality of patient care
4.22and on program costs, information regarding whether the drug is subject to clinical abuse
4.23or misuse, and relevant data from the state Medicaid program if such data is available;
4.24(2) the Formulary Committee must review the drug, taking into account medical and
4.25clinical data and the information provided by the commissioner; deleted text begin and deleted text end
4.26(3) the Formulary Committee must hold a public forum and receive public comment for
4.27an additional 15 days deleted text begin . deleted text end new text begin ; and new text end
4.28 new text begin (4) the commissioner must publicly disclose public comments received during the public new text end
4.29 new text begin comment period for each meeting on the Department of Human Services' website within new text end
4.30 new text begin 48 hours of receipt, not including weekends or holidays. All comments received must be new text end
4.31 new text begin retained and publicly available for ... years. new text end
4.32The commissioner must provide a 15-day notice period before implementing the prior
4.33authorization.
5.1(c) Except as provided in subdivision 13j, prior authorization shall not be required or
5.2utilized for any atypical antipsychotic drug prescribed for the treatment of mental illness
5.3if:
5.4(1) there is no generically equivalent drug available; and
5.5(2) the drug was initially prescribed for the recipient prior to July 1, 2003; or
5.6(3) the drug is part of the recipient's current course of treatment.
5.7This paragraph applies to any multistate preferred drug list or supplemental drug rebate
5.8program established or administered by the commissioner. Prior authorization shall
5.9automatically be granted for 60 days for brand name drugs prescribed for treatment of mental
5.10illness within 60 days of when a generically equivalent drug becomes available, provided
5.11that the brand name drug was part of the recipient's course of treatment at the time the
5.12generically equivalent drug became available.
5.13(d) Prior authorization must not be required for liquid methadone if only one version of
5.14liquid methadone is available. If more than one version of liquid methadone is available,
5.15the commissioner shall ensure that at least one version of liquid methadone is available
5.16without prior authorization.
5.17(e) Prior authorization may be required for an oral liquid form of a drug, except as
5.18described in paragraph (d). A prior authorization request under this paragraph must be
5.19automatically approved within 24 hours if the drug is being prescribed for a Food and Drug
5.20Administration-approved condition for a patient who utilizes an enteral tube for feedings
5.21or medication administration, even if the patient has current or prior claims for pills for that
5.22condition. If more than one version of the oral liquid form of a drug is available, the
5.23commissioner may select the version that is able to be approved for a Food and Drug
5.24Administration-approved condition for a patient who utilizes an enteral tube for feedings
5.25or medication administration. This paragraph applies to any multistate preferred drug list
5.26or supplemental drug rebate program established or administered by the commissioner. new text begin By new text end
5.27 new text begin August 1, 2026, new text end the commissioner shall design and implement a streamlined prior
5.28authorization form for patients who utilize an enteral tube for feedings or medication
5.29administration and are prescribed an oral liquid form of a drug new text begin . The form must include an new text end
5.30 new text begin option for a prescriber to check a box verifying that the patient utilizes an enteral tube for new text end
5.31 new text begin feedings or medication administration. This verification is sufficient to establish the need new text end
5.32 new text begin for the prior authorization automatic approval of the oral liquid form of the drug without new text end
5.33 new text begin the requirement of any additional prior authorization forms or further documentation new text end . The
5.34commissioner may require prior authorization for brand name drugs whenever a generically
6.1equivalent product is available, even if the prescriber specifically indicates "dispense as
6.2written-brand necessary" on the prescription as required by section 151.21, subdivision 2.
6.3(f) Notwithstanding this subdivision, the commissioner may automatically require prior
6.4authorization, for a period not to exceed 180 days, for any drug that is approved by the
6.5United States Food and Drug Administration on or after July 1, 2005. The 180-day period
6.6begins no later than the first day that a drug is available for shipment to pharmacies within
6.7the state. The Formulary Committee shall recommend to the commissioner general criteria
6.8to be used for the prior authorization of the drugs, but the committee is not required to
6.9review each individual drug. In order to continue prior authorizations for a drug after the
6.10180-day period has expired, the commissioner must follow the provisions of this subdivision.
6.11(g) Prior authorization under this subdivision shall comply with section 62Q.184.
6.12(h) Any step therapy protocol requirements established by the commissioner must comply
6.13with section 62Q.1841.
6.14(i) Notwithstanding any law to the contrary, prior authorization or step therapy shall not
6.15be required or utilized for any class of drugs that is approved by the United States Food and
6.16Drug Administration for the treatment or prevention of HIV and AIDS.
6.17Sec. 3. Minnesota Statutes 2024, section 256B.0625, subdivision 13g, is amended to read:
6.18Subd. 13g. Preferred drug list. (a) The commissioner shall adopt and implement a
6.19preferred drug list by January 1, 2004. The commissioner may enter into a contract with a
6.20vendor for the purpose of participating in a preferred drug list and supplemental rebate
6.21program. The terms of the contract with the vendor must be publicly disclosed on the website
6.22of the Department of Human Services. The commissioner shall ensure that any contract
6.23meets all federal requirements and maximizes federal financial participation. The
6.24commissioner shall publish the preferred drug list annually in the State Register and shall
6.25maintain an accurate and up-to-date list on the agency website. The commissioner shall
6.26implement and maintain an accurate archive of previous versions of the preferred drug list,
6.27and make this archive available to the public on the website of the Department of Human
6.28Services beginning January 1, 2024.
6.29(b) The commissioner may add to, delete from, and otherwise modify the preferred drug
6.30list deleted text begin , deleted text end after consulting with the Formulary Committee new text begin , the Rare Disease Advisory Council new text end
6.31 new text begin for a product designated as an orphan drug by the United States Food and Drug new text end
6.32 new text begin Administration (FDA) or indicated for orphan drug use by the FDA, new text end and appropriate medical
7.1specialists deleted text begin , deleted text end new text begin ; new text end providing public notice and the opportunity for public comment deleted text begin , deleted text end new text begin ; new text end and complying
7.2with the requirements of paragraph (f).
7.3(c) The commissioner shall adopt and administer the preferred drug list as part of the
7.4administration of the supplemental drug rebate program. Reimbursement for prescription
7.5drugs not on the preferred drug list may be subject to prior authorization.
7.6(d) For purposes of this subdivision, the following terms have the meanings given:
7.7(1) "appropriate medical specialist" means a medical professional who prescribes the
7.8relevant class of drug as part of their practice; and
7.9(2) "preferred drug list" means a list of prescription drugs within designated therapeutic
7.10classes selected by the commissioner, for which prior authorization based on the identity
7.11of the drug or class is not required.
7.12(e) The commissioner shall seek any federal waivers or approvals necessary to implement
7.13this subdivision.
7.14(f) Before the commissioner may delete a drug from the preferred drug list or modify
7.15the inclusion of a drug on the preferred drug list, the commissioner shall consider any
7.16implications that the deletion or modification may have on state public health policies or
7.17initiatives and any impact that the deletion or modification may have on increasing health
7.18disparities in the state. Prior to deleting a drug or modifying the inclusion of a drug, the
7.19commissioner shall also conduct a public hearing. The commissioner shall provide adequate
7.20notice to the public and the commissioner of health prior to the hearing that specifies the
7.21drug that the commissioner is proposing to delete or modify, and shall disclose any public
7.22medical or clinical analysis that the commissioner has relied on in proposing the deletion
7.23or modification and evidence that the commissioner has evaluated the impact of the proposed
7.24deletion or modification on public health and health disparities. new text begin The commissioner must new text end
7.25 new text begin publicly disclose the required analysis and evidence of evaluation compliance on the new text end
7.26 new text begin Department of Human Services' website at least 30 days before the hearing. new text end Notwithstanding
7.27section 331A.05, a public notice of a Formulary Committee meeting must be published at
7.28least 30 days in advance of the meeting. The list of drugs to be discussed at the meeting
7.29must be announced at least 30 days before the meeting and must include the name and class
7.30of drug, the proposed action, and the proposed prior authorization requirements, if applicable.

Bill information comes from public records published by the Office of the Revisor of Statutes, the Minnesota House and the Minnesota Senate. AI summaries are written by MinneSlate and are not official. MinneSlate is independent and is not affiliated with the State of Minnesota or the Minnesota Legislature.

Progress through the legislative process

17%
In Committee
Loading…